Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 308 posts found.

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024
Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …

News

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024
Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies

Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …

News

AstraZeneca to build $1.5bn ADC facility in Singapore

May 20, 2024
Manufacturing and Production ADCs, AstraZeneca, Oncology, antibody drug conjugate, manufacturing

AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), …

News

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024
Medical Communications Amgen, FDA, Oncology, lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …

News

FDA approves Roche’s HPV self-collection screening option

May 15, 2024
Medical Communications FDA, HPV, Oncology, Roche, cervical cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …

News

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024
Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024
Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …

News

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024
Research and Development Oncology, Ono Pharmaceutical, Prism BioLab, research and licensing agreement

Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the …

News

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024
Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …

News

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024
Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer

ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …

News

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024
Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …

News

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024
Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …

News

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026